Search Login Register

Zalcitabine (Hivid) Summary

Description: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

Also Known As: Hivid; 2',3' Dideoxycytidine; HIVID Roche; Hoffman-La Roche Brand of Zalcitabine; NSC-606170 Show All >>

Networked: 236 relevant articles (12 outcomes, 36 trials/studies) for this Drug

Key Diseases for which Zalcitabine is Relevant

  1. Acquired Immunodeficiency Syndrome (AIDS) : 5 outcomes 20 studies in 86 results
  2. HIV Infections (HIV Infection) : 2 outcomes 8 studies in 44 results
  3. AIDS-Related Complex (ARC) : 1 outcome 3 studies in 13 results
  4. Disease Progression : 1 outcome 3 studies in 12 results
  5. Peripheral Nervous System Diseases (PNS Diseases) : 1 outcome 2 studies in 34 results
Show All >>

Drugs Related to Zalcitabine

  1. Zidovudine (Retrovir)
  2. Didanosine (Videx)
  3. Zalcitabine (Hivid)
  4. Ritonavir (Norvir)
  5. Saquinavir (Invirase)
  6. Antigens
  7. Biological Markers (Surrogate Marker)
  8. Antiviral Agents (Antivirals)
  9. 2',3'-dideoxycytidine 5'-triphosphate
  10. Lamivudine (3TC)
Show All >>

Therapies Related to Zalcitabine

  1. Oral Administration
  2. First Aid (Aids, First)
  3. Aftercare (After-Treatment)
  4. Highly Active Antiretroviral Therapy (HAART)
  5. Drug Therapy (Chemotherapy)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.